Pertussis - Pipeline Review, H2 2015

Date: October 21, 2015
Pages: 98
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P998818F2E9EN
Leaflet:

Download PDF Leaflet

Pertussis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pertussis - Pipeline Review, H2 2015’, provides an overview of the Pertussis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pertussis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pertussis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Pertussis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pertussis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pertussis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pertussis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pertussis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Pertussis Overview
Therapeutics Development
Pipeline Products for Pertussis - Overview
Pipeline Products for Pertussis - Comparative Analysis
Pertussis - Therapeutics under Development by Companies
Pertussis - Therapeutics under Investigation by Universities/Institutes
Pertussis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pertussis - Products under Development by Companies
Pertussis - Products under Investigation by Universities/Institutes
Pertussis - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Bharat Biotech International Limited
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
DBV Technologies S.A.
GlaxoSmithKline Plc
Green Cross Corporation
Immunovaccine, Inc.
Indian Immunologicals Limited
LG Life Sciences Limited
NanoBio Corporation
Panacea Biotec Limited
Sanofi
Sanofi Pasteur SA
Serum Institute of India Limited
Sinovac Biotech Ltd.
Synthetic Biologics, Inc.
Zydus Cadila Healthcare Limited
Pertussis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(diphtheria + tetanus + pertussis (whole-cell)) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(diphtheria + tetanus + pertussis) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (whole cell) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-3111A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis (whole-cell) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis + hepatitis B vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PR-5I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant BCG - Pertussis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYN-005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VN-0103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pertussis - Recent Pipeline Updates
Pertussis - Dormant Projects
Pertussis - Discontinued Products
Pertussis - Product Development Milestones
Featured News & Press Releases
Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Oct 16, 2014: BioNet Provides Update on Recombinant Acellular Pertussis Vaccine at BioJapan 2014
Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
Apr 23, 2014: Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
Dec 20, 2012: Synthetic Biologics And Intrexon Initiate Development Of Monoclonal Antibodies For Whooping Cough
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pertussis, H2 2015
Number of Products under Development for Pertussis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Pertussis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
Pertussis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2015
Pertussis - Pipeline by Bharat Biotech International Limited, H2 2015
Pertussis - Pipeline by Biological E. Limited, H2 2015
Pertussis - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015
Pertussis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Pertussis - Pipeline by DBV Technologies S.A., H2 2015
Pertussis - Pipeline by GlaxoSmithKline Plc, H2 2015
Pertussis - Pipeline by Green Cross Corporation, H2 2015
Pertussis - Pipeline by Immunovaccine, Inc., H2 2015
Pertussis - Pipeline by Indian Immunologicals Limited, H2 2015
Pertussis - Pipeline by LG Life Sciences Limited, H2 2015
Pertussis - Pipeline by NanoBio Corporation, H2 2015
Pertussis - Pipeline by Panacea Biotec Limited, H2 2015
Pertussis - Pipeline by Sanofi, H2 2015
Pertussis - Pipeline by Sanofi Pasteur SA, H2 2015
Pertussis - Pipeline by Serum Institute of India Limited, H2 2015
Pertussis - Pipeline by Sinovac Biotech Ltd., H2 2015
Pertussis - Pipeline by Synthetic Biologics, Inc., H2 2015
Pertussis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pertussis Therapeutics - Recent Pipeline Updates, H2 2015
Pertussis - Dormant Projects, H2 2015
Pertussis - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Pertussis, H2 2015
Number of Products under Development for Pertussis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Skip to top


Pertussis - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 99 pages
Sanofi Pasteur SA - Product Pipeline Review - 2016 US$ 1,275.00 Mar, 2016 · 59 pages
Biological E. Limited - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 29 pages
DBV Technologies S.A. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 35 pages

Ask Your Question

Pertussis - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: